A FAERS database study on visual impairment adverse events associated with three long-acting insulin analogues.

Statistically significant visual impairment signals were detected across all three insulins.

Among the 5,780 specific "visual impairment" reports, over 60% involved female patients, and 93% originated from the United States.

Multivariate regression suggested that higher body weight might be a potential protective factor (P < 0.05); however, this finding may be confounded by the database's inherent limitation in differentiating between Type 1 and Type 2 diabetes characteristics.